Valuation: Penumbra, Inc.

Market Cap 12.65B 11B 10.24B 9.4B 17.75B 1,208B 18.02B 121B 47.36B 601B 47.51B 46.47B 2,016B P/E 2026 *
63.8x
P/E 2027 * 51.8x
Enterprise Value 12.11B 10.53B 9.8B 9B 16.99B 1,156B 17.26B 116B 45.34B 576B 45.49B 44.49B 1,930B EV / Sales 2026 *
7.59x
EV / Sales 2027 * 6.62x
Free-Float
96.96%
Yield 2026 *
-
Yield 2027 * -
1 day+0.43%
1 week+0.77%
1 month+0.82%
3 months-1.27%
6 months-10.03%
Current year+3.31%
1 week 317.09
Extreme 317.09
323.05
1 month 315.69
Extreme 315.69
323.05
Current year 290
Extreme 290
362.41
1 year 221.26
Extreme 221.26
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 56.05
Extreme 56.05
362.41
Manager TitleAgeSince
Chief Executive Officer 64 2004-06-20
President 41 2025-08-31
Director of Finance/CFO 54 2019-12-01
Director TitleAgeSince
Chairman 64 2014-12-31
Chairman 64 2004-12-31
Director/Board Member 59 2015-03-31
Date Insider Type Main position Quantity % Market Cap.
2/13/26 Free

Founder

589 0.0015%
2/13/26 Free

Director

589 0.0015%
2/13/26 Free

General Counsel

5,742 0.0146%
Change 5-day change 1-year change 3-year change Capi.($)
+0.43%+0.77%+32.17%+19.20% 12.65B
-0.36%+3.30%+24.91%+22.38% 6.78B
-0.95%+0.28%+50.77%+25.89% 5.98B
-0.52%+7.25% - - 5.07B
+3.47%+9.59%-18.67%+46.80% 4.75B
+0.32%+5.56%-19.89%-16.58% 4.15B
-0.49%+4.41%-19.08%+206.73% 1.84B
-2.56%-15.92%+31.10%-50.68% 1.73B
+1.32%-3.76%+58.51%-7.38% 1.58B
+2.67%+6.90%-27.21%-50.15% 1.27B
Average +0.33%+2.30%+12.51%+21.80% 4.58B
Weighted average by Cap. +0.28%+3.29%+19.28%+22.58%

Financials

2026 *2027 *
Net sales 1.6B 1.39B 1.29B 1.19B 2.24B 152B 2.27B 15.22B 5.97B 75.83B 5.99B 5.86B 254B 1.8B 1.57B 1.46B 1.34B 2.53B 172B 2.57B 17.19B 6.75B 85.64B 6.77B 6.62B 287B
Net income 181M 157M 146M 134M 254M 17.27B 258M 1.73B 677M 8.6B 679M 664M 28.83B 245M 213M 198M 182M 344M 23.39B 349M 2.34B 917M 11.64B 920M 900M 39.04B
Net Debt -538M -468M -435M -400M -755M -51.34B -766M -5.13B -2.01B -25.56B -2.02B -1.98B -85.71B -729M -633M -590M -541M -1.02B -69.56B -1.04B -6.95B -2.73B -34.63B -2.74B -2.68B -116B
Logo Penumbra, Inc.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
Employees
4,700
Date Price Change Volume
26-07-31 US$321.19 +0.43% 295,954
26-07-30 US$319.83 -0.09% 357,943
26-07-29 US$320.13 +0.04% 365,272
26-07-28 US$319.99 +0.16% 457,807
26-07-27 US$319.49 +0.24% 338,837
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
321.19USD
Average target price
361.58USD
Spread / Average Target
+12.58%

Quarterly revenue - Rate of surprise